ATNF: 180 Life Sciences Corp. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.41
Enterprise Value ($M) 2.54
Book Value ($M) -0.95
Book Value / Share -1.12
Price / Book -1.47
NCAV ($M) -2.54
NCAV / Share -2.98
Price / NCAV -0.55

Profitability (mra)
Return on Invested Capital (ROIC) -18.98
Return on Assets (ROA) -1.09
Return on Equity (ROE) -2.27

Liquidity (mrq)
Quick Ratio 0.45
Current Ratio 0.45

Balance Sheet (mrq) ($M)
Current Assets 1.85
Assets 3.44
Liabilities 4.40
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -13.48
Net Income -19.94
Earnings Per Share Diluted n/a
Earnings Per Share Nonrecurring Common Control Intra Entity Transactions Description n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -10.92
Cash from Investing 0.00
Cash from Financing 5.91

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-14 13G Armistice Capital, Llc 9.99

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q
2023-08-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-06-21 2,440 30,381 8.03
2024-06-20 4,825 21,088 22.88
2024-06-18 16,704 53,299 31.34
2024-06-17 245,521 647,350 37.93

(click for more detail)

Similar Companies
ARTL – Artelo Biosciences, Inc. ASNS – Actelis Networks, Inc.
ASRT – Assertio Holdings, Inc. ATOS – Atossa Therapeutics, Inc.
ATXI – Avenue Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io